Rob Jacob


Rob is a partner specialising in both contentious and non-contentious IP issues with a particular focus on trade mark and copyright matters. He has particular expertise in the life sciences sector. Rob has a masters degree in Chemistry from Imperial College, London and a post-graduate diploma in IP law and practice. He is a recommended lawyer in the Legal 500 UK directory for intellectual property and pharmaceuticals and biotechnology with “notable strengths in trade mark work” and has been described as “a very brainy guy who thinks deeply about his cases”. 

Rob is also ranked in The Legal 500 2021 as a next generation trade mark partner.

Rob’s life sciences experience includes advising:

  • GlaxoSmithKline on a multi-jurisdictional claim running in over 30 countries worldwide against multiple defendants in relation to the enforcement of GSK’s rights regarding the use of non-traditional trade marks, and in particular the colour and shape of an asthma inhaler.
  • BTG plc on the public takeover of Biocompatibles plc.
  • Piramal Enterprises on the US$3.8 billion sale of domestic formulations division to US pharmaceuticals giant Abbott.
  • Bayer Pharma AG on the acquisition of the worldwide rights of Florbetaben (a pioneering molecular imaging product for the diagnosis of early Alzheimer's disease).

Rob Jacob is absolutely brilliant. He is always incredibly responsive with detailed advice that is super-thoughtful and nuanced but also practical and on-point.

Chambers UK 2024